search
Back to results

The Oral Microbiome in OSCC

Primary Purpose

Oral Cancer

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
ProDentis Lozenge
Placebo Lozenge
Sponsored by
University of Iowa
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Oral Cancer

Eligibility Criteria

21 Years - 89 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adults (21-70 years old) who have been diagnosed with oral dysplasia or that have been treatment-planned as wait and watch or
  2. Adults (21-70 years old) or who have been diagnosed with oral squamous cell carcinoma, or matched healthy controls free of any oral lesions

Exclusion Criteria:

  1. Adults who have had a course of antibiotics that was completed less than 3 months prior to the study;
  2. Adults with any immunosuppressive condition or medication that would put the subject at risk of consuming daily probiotics;
  3. Adults who regularly use probiotic dietary supplements
  4. Adults that have alcohol/tobacco use history that does not match study population - this if for the healthy controls arm only.

Sites / Locations

  • University of Iowa College of Dentistry and Dental Clinics

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Probiotic Lozenge

Placebo Lozenge

Arm Description

Outcomes

Primary Outcome Measures

Assessment of changes in the oral microbiome composition over time
16S Genomic Profiling will be done in all recruited subjects via oral swab of pre-cancerous or cancerous oral lesion
Determine the Effect of ProDentis on the Oral Microbiome
Pre-Cancerous lesion is treatment planned as "watch-and-wait" or oral lesion is not present, recruited subjects will be randomly assigned to either the probiotic lozenge or placebo lozenge group.

Secondary Outcome Measures

Full Information

First Posted
May 27, 2021
Last Updated
August 14, 2023
Sponsor
University of Iowa
search

1. Study Identification

Unique Protocol Identification Number
NCT04925700
Brief Title
The Oral Microbiome in OSCC
Official Title
The Oral Microbiome in Oral Squamous Cell Carcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 20, 2022 (Actual)
Primary Completion Date
September 1, 2023 (Anticipated)
Study Completion Date
December 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Iowa

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Previous work by a number of scientific teams has revealed that the types of bacteria that colonize the mouth differ between health and pre-cancerous or cancerous oral lesions. The purpose of this study is to investigate the extent of these changes and to correlate the changes with alterations in the activities of the host's own oral tissues. In doing so, we believe we can gain a better understanding of how particular bacterial species, or consortia of species, can result in an individual having an increased risk of the most common type of oral cancer -- oral squamous cell carcinoma. This knowledge may also lead to the identification of salivary biomarkers that can be used for clinical evaluation or screening. In addition, we seek to determine the extent to which a probiotic regimen can help prevent or rectify the disease-related changes in the types of bacterial colonizing the mouth. The microbiome in health, pre-cancerous lesions, and cancerous lesions will be determined from remnant microbial DNA in banked tissue samples. The effects of probiotics on the oral microbiome will be determined from DNA collected from swabs of oral tissue at baseline and then after 3 to 6 months of probiotic usage.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Oral Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Probiotic Lozenge
Arm Type
Experimental
Arm Title
Placebo Lozenge
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
ProDentis Lozenge
Intervention Description
1-2 ProDentis Lozenges per day
Intervention Type
Other
Intervention Name(s)
Placebo Lozenge
Intervention Description
1-2 Placebo Lozenges per day
Primary Outcome Measure Information:
Title
Assessment of changes in the oral microbiome composition over time
Description
16S Genomic Profiling will be done in all recruited subjects via oral swab of pre-cancerous or cancerous oral lesion
Time Frame
Up to 3 months
Title
Determine the Effect of ProDentis on the Oral Microbiome
Description
Pre-Cancerous lesion is treatment planned as "watch-and-wait" or oral lesion is not present, recruited subjects will be randomly assigned to either the probiotic lozenge or placebo lozenge group.
Time Frame
Up to 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
89 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults (21-70 years old) who have been diagnosed with oral dysplasia or that have been treatment-planned as wait and watch or Adults (21-70 years old) or who have been diagnosed with oral squamous cell carcinoma, or matched healthy controls free of any oral lesions Exclusion Criteria: Adults who have had a course of antibiotics that was completed less than 3 months prior to the study; Adults with any immunosuppressive condition or medication that would put the subject at risk of consuming daily probiotics; Adults who regularly use probiotic dietary supplements Adults that have alcohol/tobacco use history that does not match study population - this if for the healthy controls arm only.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Drake, MS, PhD
Organizational Affiliation
University of Iowa College of Dentistry
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Iowa College of Dentistry and Dental Clinics
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States

12. IPD Sharing Statement

Learn more about this trial

The Oral Microbiome in OSCC

We'll reach out to this number within 24 hrs